However, further development of CRISP-DM seems to have stalled, with only a 1.0 version fully produced almost two decades ago, and rumors of a second version under way almost fifteen years ago. IBM and Microsoft have both iterated on the methodologies to produce their own variants that add more detail with respect to more iterative loops between data processing and modeling and more specifics around artifacts and deliverables produced during the process. However, both companies are primarily leveraging their modifications in the context of delivering their own premium service engagements or as part of product-centric implementation processes. Clearly vendor-centric, proprietary methodologies can’t be adopted by organizations that have diverse technology needs or desire to utilize vendor-agnostic approaches to technology implementation.
The changes are the company’s biggest — and actually, only — big executive shakeup since LinkedIn was acquired by Microsoft for $26.2 billion in 2016. It’s notable that both of the new appointments are of long-time LinkedIn executives — don’t rock the boat too much, don’t fix what isn’t broken, and all that.
Like the old Microsoft-Intel relationship of the PC era, they believe they have the symbiotic relationship necessary to usher in a new era where anybody can inexpensively create their own life forms. Genome Compiler is backed with $3 million in funding, including $2 million from Autodesk. Cambrian is funded by Founders Fund, Felicis Ventures and Draper Associates.
Enter Synthace, the startup developing Antha, a language and software platform specifically for biology. In 2018, the company raised a £26 million series B round led by Horizons Ventures, to continue to develop their cloud software platform. With clients and partners such as Microsoft, Merck, Oxford Biomedica, LabGenius and Princeton, the company is fast becoming the pioneer in so-called "Computer-Aided Biology."